Understanding Δ8-THC: Insights from Dr. Mark A. Scialdone

Dr. Mark A. Scialdone is a renowned expert in organic chemistry with a focus on natural product chemistry. With 37 US patents and 17 peer-reviewed articles to his name, he has made significant contributions to the field. His association with DuPont Central Research and Development and his achievements in the Cannabis Chemistry Subdivision of the American Chemical Society further solidify his expertise. Currently, he leads BetterChem Consulting, offering services in various industries including cannabis and hemp.

Chemical conversion of CBD into Δ8-THC

At the International Cannabinoid Research Society conference in Toronto, Dr. Scialdone discussed the chemical conversion of CBD into Δ8-THC and the emergence of numerous THC isomers. Isomers are molecules with the same atoms but different arrangements, leading to varied chemical and physical properties. The Δ8-THC produced from CBD conversion contains multiple non-natural THC isomers, which are not found in cannabis. These isomers pose potential health risks and are challenging to measure and purify.

Concerns about byproducts

Beyond the THC isomers, the conversion process also results in other byproducts. Recent tests on commercial Δ8-THC products have detected degradation products and chlorinated compounds. The lack of regulatory oversight for the conversion process raises concerns about product safety and standardization.

Δ8-THC pre-rolls and concerns

Advertisements for “Δ8-THC pre-rolls” raise questions about the production process. Concerns include the methods used to add Δ8-THC to the pre-rolls, the purity of the Δ8-THC, and the solvents used. The production cost and profit margins for these products also come under scrutiny.

Emergence of new synthetic compounds

Δ8-THC has paved the way for a range of unregulated synthetic compounds. While only Δ8, Δ9, and Δ10 THC can be derived from hemp, other compounds are produced through chemical conversion. The sale of these psychoactive products outside regulated frameworks is ethically questionable. The demand for these products is a direct result of cannabis prohibition, and ending this prohibition could diminish their market presence.

Future of Δ8-THC in the Farm Bill

The upcoming iteration of the Farm Bill needs to address the legality of Δ8-THC and other synthetic intoxicants. The USDA's authority over hemp concludes at harvest, leaving the FDA to regulate hemp-derived CBD products. The Farm Bill should clearly differentiate between high Δ9-THC cannabis and industrial hemp and address the sale of synthesized cannabinoids.